Onyx Biotec Past Earnings Performance
Past criteria checks 3/6
Onyx Biotec has been growing earnings at an average annual rate of 64.4%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 36.1% per year. Onyx Biotec's return on equity is 12.2%, and it has net margins of 5.6%.
Key information
64.4%
Earnings growth rate
62.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 36.1% |
Return on equity | 12.2% |
Net Margin | 5.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Onyx Biotec makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 537 | 30 | 60 | 0 |
31 Mar 23 | 395 | 18 | 105 | 0 |
31 Mar 22 | 449 | 34 | 87 | 0 |
Quality Earnings: ONYX has high quality earnings.
Growing Profit Margin: ONYX's current net profit margins (5.6%) are higher than last year (4.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ONYX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ONYX's past year earnings growth to its 5-year average.
Earnings vs Industry: ONYX earnings growth over the past year (64.4%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: ONYX's Return on Equity (12.2%) is considered low.